TY  - GEN 
AU  - Dodero-Anillo, Jose Manuel
AU  - Fernandez-Pujol-Marzo, Marta
AU  - Pedrosa Martínez, María José
AU  - Ruiz-Villaverde, Ricardo
AU  - Armario Hita, José Carlos
A4  - Medicina
A4  - Neurociencias
PY  - 2026
SN  - 2077-0383
UR  - http://hdl.handle.net/10498/40543
AB  - Background: Guselkumab, a selective anti-IL-23p19 monoclonal antibody, has shown high efficacy in randomized trials for moderate-to-severe psoriasis and active psoriatic arthritis (PsA). Real-world evidence is essential to assess treatment performance...
LA  - eng
PB  - MDPI
KW  - guselkumab
KW  - psoriasis
KW  - psoriatic arthritis
KW  - real-world evidence
KW  - systematic review
KW  - meta-analysis
KW  - IL-23
KW  - PASI
KW  - DAPSA
TI  - Efficacy and Safety of Guselkumab in Real-World Evidence: A Systematic Review and Meta-Analysis
DO  - 10.3390/JCM15103692
ER  -